Last reviewed · How we verify
Capecitabine plus temozolamide
Capecitabine and temozolamide are chemotherapy agents that work together to inhibit DNA synthesis and induce cell death in cancer cells.
Capecitabine and temozolamide are chemotherapy agents that work together to inhibit DNA synthesis and induce cell death in cancer cells. Used for Glioblastoma multiforme (Phase 3 trial), Brain tumors.
At a glance
| Generic name | Capecitabine plus temozolamide |
|---|---|
| Also known as | CAPE-TEM |
| Sponsor | Tata Memorial Hospital |
| Drug class | Chemotherapy combination (fluoropyrimidine + alkylating agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is a fluoropyrimidine carbamate that is converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. Temozolamide is an alkylating agent that methylates DNA at the O6 position of guanine, causing DNA strand breaks and apoptosis. The combination leverages different mechanisms of cytotoxicity to enhance anti-tumor activity.
Approved indications
- Glioblastoma multiforme (Phase 3 trial)
- Brain tumors
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Hand-foot skin reaction
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine plus temozolamide CI brief — competitive landscape report
- Capecitabine plus temozolamide updates RSS · CI watch RSS
- Tata Memorial Hospital portfolio CI